What is the appropriate treatment for hyperkalemia?

Hyperkalemia Treatment

Treat hyperkalemia immediately with a three-step approach: cardiac membrane stabilization with IV calcium, intracellular potassium shift using insulin-glucose and albuterol, and definitive potassium removal via diuretics, potassium binders, or hemodialysis—with the specific interventions determined by severity, ECG changes, and renal function. 1

---

Severity Classification

Before initiating treatment, classify hyperkalemia severity to guide therapeutic intensity:

• Mild hyperkalemia: 5.0-5.9 mEq/L 1
• Moderate hyperkalemia: 6.0-6.4 mEq/L 1
• Severe hyperkalemia: ≥6.5 mEq/L, which is life-threatening 1
• ECG changes indicate urgent treatment regardless of potassium level, including peaked T waves, flattened P waves, prolonged PR interval, and widened QRS 1

---

Step 1: Cardiac Membrane Stabilization (Immediate—Within Minutes)

Administer IV calcium first if potassium >6.5 mEq/L OR any ECG changes are present. 1

• Calcium gluconate 10%: 15-30 mL IV over 2-5 minutes (preferred for peripheral access) 1
• Calcium chloride 10%: 5-10 mL (500-1000 mg) IV over 2-5 minutes (more potent; use via central line when possible to avoid tissue injury from extravasation) 1
• Onset: 1-3 minutes; Duration: 30-60 minutes 1, 2
• Calcium does NOT lower serum potassium—it only stabilizes cardiac membranes temporarily 1
• Repeat the dose if no ECG improvement within 5-10 minutes 2
• Continuous cardiac monitoring is mandatory during administration 1

Critical Precautions for Calcium Administration

• Never mix calcium with sodium bicarbonate in the same IV line—precipitation will occur 1
• Use calcium cautiously in patients with elevated serum phosphate (e.g., tumor lysis syndrome), as it increases the risk of calcium-phosphate precipitation in tissues 1
• Monitor heart rate during infusion and stop if symptomatic bradycardia occurs 1

---

Step 2: Shift Potassium into Cells (Onset 15-30 Minutes)

Administer all three agents simultaneously for maximum effect:

Insulin-Glucose Therapy

• 10 units regular insulin IV with 25g glucose (50 mL of D50W) over 15-30 minutes 1
• Lowers potassium by 0.5-1.2 mEq/L within 30-60 minutes 3
• Effect lasts 4-6 hours 1
• Never give insulin without glucose—hypoglycemia can be fatal 1, 2
• Monitor blood glucose closely, especially in patients with low baseline glucose, no diabetes history, female sex, or impaired renal function 1
• Recheck potassium within 1-2 hours after administration 1

Nebulized Albuterol

• 10-20 mg albuterol in 4 mL nebulized over 10-15 minutes 1
• Lowers potassium by 0.5-1.0 mEq/L within 30 minutes 1, 3
• Duration: 2-4 hours 1
• Can be repeated every 2 hours if needed 1
• Most common side effect: sinus tachycardia 1
• Combined insulin-glucose plus albuterol is more effective than either alone 3

Sodium Bicarbonate (ONLY with Metabolic Acidosis)

• 50 mEq IV over 5 minutes ONLY if pH <7.35 and bicarbonate <22 mEq/L 1, 2
• Onset: 30-60 minutes 1
• Do NOT use without documented metabolic acidosis—it is ineffective and wastes time 1, 2

---

Step 3: Eliminate Potassium from Body (Definitive Treatment)

Loop Diuretics (If Adequate Renal Function)

• Furosemide 40-80 mg IV 1
• Effective only in patients with eGFR >30 mL/min and adequate urine output 1
• Increases renal potassium excretion by stimulating flow to renal collecting ducts 2

Hemodialysis (Most Effective Method)

Hemodialysis is the gold standard for severe hyperkalemia and should be initiated urgently for: 1, 2

• Serum potassium >6.5 mEq/L unresponsive to medical therapy
• Oliguria or anuria
• End-stage renal disease
• Ongoing potassium release (tumor lysis syndrome, rhabdomyolysis)
• Severe renal impairment (eGFR <15 mL/min)
• Persistent ECG changes despite medical management

In hemodynamically unstable patients, continuous renal replacement therapy (CRRT) is preferred over intermittent hemodialysis to minimize rapid fluid shifts and reduce intradialytic hypotension risk 1

Potassium Binders (Sub-Acute Management)

Newer potassium binders are safer and more effective than sodium polystyrene sulfonate:

• Sodium zirconium cyclosilicate (SZC/Lokelma):

  • 10 g three times daily for 48 hours, then 5-15 g once daily for maintenance 1, 2
  • Onset: ~1 hour (suitable for urgent scenarios) 1, 2
  • Reduces serum potassium within 1 hour of a single 10-g dose 2

• Patiromer (Veltassa):

  • 8.4 g once daily with food, titrated up to 25.2 g daily 1, 2
  • Onset: ~7 hours (for sub-acute/chronic control) 1, 2
  • Must be separated from other oral medications by ≥3 hours 1, 2

• Sodium polystyrene sulfonate (Kayexalate):

  • Avoid due to risk of bowel necrosis, colonic ischemia, and limited efficacy data 1, 2, 4

---

Medication Management During Acute Episode

Temporarily discontinue or reduce the following when potassium >6.5 mEq/L: 1, 2

• RAAS inhibitors (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists)
• NSAIDs
• Potassium-sparing diuretics
• Trimethoprim-containing agents
• Heparin
• Beta-blockers
• Potassium supplements and salt substitutes

After acute resolution (potassium <5.0 mEq/L):

• Restart RAAS inhibitors at a lower dose 1, 2
• Initiate a potassium binder (SZC or patiromer) to enable continuation of life-saving RAAS therapy, which provides mortality benefit in cardiovascular and renal disease 1, 2

---

Monitoring Protocol

Acute Phase

• Recheck potassium 1-2 hours after insulin/glucose or albuterol therapy 1
• Continue potassium checks every 2-4 hours until stable 1
• Obtain repeat ECG to confirm resolution of cardiac changes 1

Post-Acute Phase

• Check potassium within 1 week after initiating or escalating RAAS inhibitors 1, 2
• Reassess 7-10 days after starting a potassium binder 1, 2
• Individualize monitoring frequency based on eGFR, heart failure, diabetes, or history of hyperkalemia 1, 2

---

Critical Pitfalls to Avoid

• Do NOT delay calcium administration while awaiting repeat potassium levels if ECG changes are present—ECG changes indicate urgent need regardless of the exact potassium value 1, 2
• Never give insulin without glucose—hypoglycemia can be fatal 1, 2
• Recognize that calcium, insulin, and albuterol are temporizing measures only—they do NOT remove potassium from the body 1, 5, 6
• Do NOT use sodium bicarbonate without documented metabolic acidosis (pH <7.35, bicarbonate <22 mEq/L) 1, 2
• Do NOT permanently discontinue RAAS inhibitors—use potassium binders to maintain these life-saving medications 1, 2
• Do NOT rely solely on ECG findings—they are highly variable and less sensitive than laboratory tests 2

---

Special Considerations

Chronic or Recurrent Hyperkalemia

• For patients on RAAS inhibitors with potassium 5.0-6.5 mEq/L: Initiate an approved potassium-lowering agent (patiromer or SZC) and maintain RAAS inhibitor therapy unless alternative treatable etiology is identified 1
• For severe hyperkalemia (>6.5 mEq/L) in patients on RAAS inhibitors: Discontinue or reduce RAAS inhibitor temporarily, initiate potassium-lowering agent when levels >5.0 mEq/L, and monitor potassium levels closely 1

Rebound Hyperkalemia

• Temporary measures (insulin/glucose, albuterol) provide only transient effects (1-4 hours), and rebound hyperkalemia can occur after 2 hours 1
• Initiate potassium-lowering agents as early as possible to prevent rebound 1

DNR Orders

• DNR orders do NOT preclude urgent dialysis for severe hyperkalemia—they apply only to cardiopulmonary resuscitation, not to other medical interventions 1